<DOC>
	<DOCNO>NCT01784913</DOCNO>
	<brief_summary>In study , 21 patient metastatic prostate cancer receive UV1 ( therapeutic synthetic peptide vaccine ) different dose level . The safety tolerability UV1 well immunological response assess . The purpose study select biological dose peptide clinical trial . Main treatment period complete report . Follow-up ongoing .</brief_summary>
	<brief_title>A Phase I/IIa Study UV1 Vaccine Patients With Prostate Cancer</brief_title>
	<detailed_description>The study open label dose-escalating phase I/IIa study UV1 peptide vaccination patient androgen-sensitive metastatic prostate cancer . Patients prospectively enrol study diagnosis adenocarcinoma histologically confirm eligible ( already start 6 month prior inclusion ) standard GnRH-agonist first line androgen deprivation therapy ( ADT ) combine anti-androgen achieve complete androgen blockade ( CAB ) . UV1 vaccination apply simultaneously CAB . When indicated , patient may receive concomitant radiotherapy . The following 2-step design use : 1 . Conventional dose escalation least 3 patient per dose level ( 3 select dose level ) . 2 . Expansion dose level total 7 patient assessment immune response level 13 UV1 vaccination give first 6 month ( week 26 ) treatment , unless clinical deterioration unacceptable toxicity encounter . GM-CSF ( Leukine ® ) administer locally 10-15 minute UV1 vaccination . Hormone naïve patient receive standard complete androgen blockade GnRH-agonist ( 3 month depot formulation sc . ) bicalutamide 50 mg orally per day ( CAB ) . Patients already GnRH-agonist therapy continue initial treatment addition bicalutamide 50 mg orally per day .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Patients advance oligometastatic prostate cancer ( PCa ) without lung and/or liver metastases eligible CAB ( GnRHagonist combine antiandrogen ) Patients already GnRHagonist must history sPSA &lt; 200 ng/mL prior start GnRHagonist treatment . GnRHagonist without bicalutamide initiate 6 month prior inclusion . Must ambulatory ECOG performance status 0 1 contraindication MRI ( pacemaker , claustrophobia , metal splint ) . Must least 18 year age . Must lab value follow : White Blood Cells ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ≥ 9g/dL ( ≥ 5.6 mmol/L ) Creatinine ≤ 140 µmol/L ; creatinine borderline , creatinine clearance ≥ 40 mL/min ; Bilirubin &lt; 20 % upper limit normal ASAT ALAT ≤ 1.5 upper limit normal Albumin ≥ 2.5 g/L Normal NSE sPSA &lt; 200 ng/mL . Signed informed consent History prior malignancy , exception curatively treat basal cell squamous cell carcinoma skin effectively treat malignancy remission 5 year highly likely cure . Treatment investigational medicinal product ( IMP ) within 4 week prior first administration study drug . Adverse reaction vaccine anaphylaxis serious reaction . History immunodeficiency autoimmune disease rheumatoid arthritis , systemic lupus erythematosus , sclerodermia , polymyositisdermatomyositis , juvenile onset insulindependent diabetes , vasculitic syndrome . Significant cardiac medical illness would limit activity survival , severe congestive heart failure , unstable angina , serious cardiac arrhythmia . Active infection require antibiotic therapy . Known hypersensitivity component vaccine Known hypersensitivity Leukine® , yeast derived product component product Patients test positive hepatitis B , C HIV Any antitumor treatment ( include chemotherapy , immunotherapy , cytokine , interferon , protease inhibitor gene therapy ) administer exception GnRHagonist without bicalutamide start 6 month prior inclusion . Use permit concomitant medication : chronic corticosteroid except asthma inhaler / topical use agent know effect immune system , unless give dose level immunesuppressive , e.g . prednisone 10mg/day less alternative complementary drug may affect immune system potentially harmful patient participate phase I study . Any reason , opinion investigator , patient participate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>vaccine</keyword>
</DOC>